# Treatment Optimization in Patients With Untreated Multiple Myeloma

> **NCT02145598** · PHASE2,PHASE3 · TERMINATED · sponsor: **Dr. med. Lars-Olof Muegge** · enrollment: 85 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02145598
- **Lead sponsor:** Dr. med. Lars-Olof Muegge
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08
- **Primary completion:** 2017-12-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Insufficient recruitment
- **Last updated:** 2019-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145598, "Treatment Optimization in Patients With Untreated Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02145598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*